These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Development of novel antiatherogenic biaryls: design, synthesis, and reactivity.
    Author: Delomenède M, Bedos-Belval F, Duran H, Vindis C, Baltas M, Nègre-Salvayre A.
    Journal: J Med Chem; 2008 Jun 12; 51(11):3171-81. PubMed ID: 18465848.
    Abstract:
    On the basis of the 5,5'-bisvanillin scaffold, a series of compounds has been synthesized presenting symmetric or dissymmetric frames on each phenolic moiety. These frames are alpha,beta-unsaturated (fluoro)phosphonate and/or alpha,beta-unsaturated hydrazone(s) formed by coupling aldehydic with isoniazid or hydralazine. All compounds were tested for their ability to inhibit cell-mediated low-density lipoprotein oxidation. Oxidized low-density lipoprotein induced cytotoxicity was also evaluated along with the carbonyl scavenger properties of selected compounds. The most efficient agents were found to be those possessing at least one hydralazinone frame, with the most potent being the symmetrical compound: 4,4'-dihydroxy-3,3'-dimethoxy-5,5'-biphenyl-1,1'-(diphthalazin-1-yl)methylhydrazone hydrochloride.
    [Abstract] [Full Text] [Related] [New Search]